Raynauds Disease – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides data on the Raynaud disease clinical trial scenario. This report provides top-line data relating to the clinical trials on Raynaud Disease. The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).
Raynauds Disease clinical trial report consists of 114 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 4, 14, 25, 25, and 2 respectively. Similarly, the trials with different status compile of Completed – 93, Ongoing – 6, Planned – 4, Terminated – 4, and Withdrawn – 7. Out of 93 completed trials, 33 trials have achieved endpoints.
What are the market dynamics of the global Raynaud disease therapeutics clinical trials sector?
The number of Raynaud’s disease clinical trials conducted globally, has decreased by 43% for the period 2016-2020. The average number of patients enrolled was highest in the year 2017. As of December 2021, the majority of the trials have been sponsored by companies followed by the institution. Out of 93 completed trials, 48 trials have results and 33 (69%) of trials reached endpoints. There were six clinical trials in progress and 93 trials are completed. The trials that were terminated/suspended or withdrawn accounted for 11. This was due to the lack of efficacy, safety, and lack of accrual of subjects. There were six clinical trials in progress of which 67% (four trials) were in Phase II study. There were 47 clinical trials in Phase II, of which four clinical trials were in progress for the time period 1995-2021.
What are the top regions and countries in the global Raynaud’s disease therapeutics clinical trials sector?
In total there were 114 clinical trials conducted on Raynaud disease, as of December 2021, of these 53 clinical trials were in Europe. More than 45% of the clinical trials were conducted in Europe.
Asia-Pacific: In the Asia-Pacific region, China, India, Japan, and South Korea have the highest number of Raynaud disease clinical trials, as of December 2021.
Europe: Among the European countries, the UK has the highest number of Raynaud disease clinical trials, as of December 2021, followed by Russia, France, Germany, and Italy.
North America: In the country-wise analysis, the US has the highest number of Raynaud disease clinical trials, as of December 2021 followed by Canada and Mexico.
Middle East & Africa: Iran has the highest number of Raynaud disease clinical trials, as of December 2021 followed by Egypt.
Central and South America: Brazil, Chile, and Colombia have the highest number of Raynaud disease clinical trials, as of December 2021.
G7 countries: Among the G7 (The US, the UK, Germany, France, Italy, Canada, and Japan) countries, France has the highest proportion of Raynaud disease in cardiovascular clinical trials as of December 2021. In total there were 78 clinical trials conducted on Raynaud Disease, as of December 2021 in G7 Countries, of these 34 clinical trials were in the US. There were four clinical trials in progress and 63 trials are completed. The trials that are terminated/suspended or withdrawn accounted to four. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Raynaud disease in cardiovascular clinical trials as of December 2021. In total there were 18 clinical trials conducted on Raynaud Disease, as of December 2021 in E7 Countries, of these 10 clinical trials were in Russia. There were zero clinical trials in progress and 14 trials were completed. The trials that were terminated/suspended or withdrawn accounted to two. This was due to the lack of efficacy, safety, and lack of accrual of subjects.
Global Raynaud disease therapeutics clinical trials sector, by regions
For more regional insights, download a free report sample
Which are the key companies in the global Raynaud disease therapeutics clinical trials sector?
As of December 2021, MediQuest Therapeutics, Inc. (Inactive) sponsored the highest number of Raynaud disease clinical trials, followed by Orion Corp. Other major companies in the sector are Johnson & Johnson, Covis Pharmaceuticals Inc, Pfizer Inc, Seelos Therapeutics, Inc., Atoll, Forenap Pharma E.U.R.L. (Inactive), Otsuka Holdings Co Ltd, and AbbVie Inc.
Global Raynaud disease therapeutics clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key countries | The US, the UK, Russia, France, Germany, Italy, Canada, the Netherlands, China, and Finland |
Key companies | MediQuest Therapeutics, Inc. (Inactive), Orion Corp., Johnson & Johnson, Covis Pharmaceuticals Inc, Pfizer Inc, Seelos Therapeutics, Inc., Atoll, Forenap Pharma E.U.R.L. (Inactive), Otsuka Holdings Co Ltd, and AbbVie Inc. |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and Endpoint status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for un-accomplishment.
- The report provides enrollment trends for the past five years.
- Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
Orion Corp
Johnson & Johnson
Covis Pharmaceuticals Inc
Pfizer Inc
Seelos Therapeutics, Inc.
Atoll
Forenap Pharma E.U.R.L. (Inactive)
Otsuka Holdings Co Ltd
AbbVie Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key countries in the global Raynaud disease therapeutics clinical trials sector?
The key countries in the global Raynaud disease therapeutics clinical trials sector are the US, the UK, Russia, France, Germany, Italy, Canada, the Netherlands, China, and Finland.
-
Which are the key companies in the global Raynaud disease therapeutics clinical trials sector?
The key companies in the global Raynaud disease therapeutics clinical trials sector are MediQuest Therapeutics, Inc. (Inactive), Orion Corp., Johnson & Johnson, Covis Pharmaceuticals Inc, Pfizer Inc, Seelos Therapeutics, Inc., Atoll, Forenap Pharma E.U.R.L. (Inactive), Otsuka Holdings Co Ltd, and AbbVie Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Cardiovascular reportsRaynauds Disease – Global Clinical Trials Review, H1, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData's clinical trial report, “Raynauds Disease – Global Clinical Trials Review, H1, 2021" provides an overview of Raynauds Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Raynauds Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Orion Corp
Johnson & Johnson
Covis Pharmaceuticals Inc
Pfizer Inc
Seelos Therapeutics, Inc.
Atoll
Forenap Pharma E.U.R.L. (Inactive)
Otsuka Holdings Co Ltd
AbbVie Inc
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.